Medistem Files Registration Statement With Securities and Exchange Commission

Medistem Files Registration Statement With Securities and Exchange Commission 
Clinical-Stage Stem Cell Company to Re-Enter Public Capital Markets 
SAN DIEGO, CA -- (Marketwired) -- 07/15/13 --  Medistem, Inc.
(PINKSHEETS: MEDS), announced today that it has filed a Form 10
registration statement with the Securities and Exchange Commission.
The filing is part of the Company's strategy to become fully
reporting and access the public capital markets. It is expected that
the Form 10 will become effective 60 days from the filing date,
allowing liquidity for existing shareholders. 
In 2009, the Company voluntarily elected to stop reporting under the
1934 Securities and Exchange Act to focus its resources on advancing
its lead product, ERC-124, a universal donor stem cell. The Company
successfully obtained FDA clearance to initiate clinical trials for
its product in patients with critical limb ischemia (CLI). In
addition, the Company has treated 18 congestive heart failure (CHF)
patients in an ongoing double-blind placebo controlled trial.  
On October 2012, the Company strengthened its management team with
the addition of biopharmaceutical veteran Alan J. Lewis, Ph.D. as
Chief Executive Officer. Dr. Lewis has previously served as CEO and
Chairman of Ambit BioSciences, CEO of the Juvenile Diabetes Research
Foundation, President, CEO and Director of Novocell, Inc., and CEO
and Director of Signal Pharmaceuticals. Dr. Lewis also serves as a
Director of BioMarin Pharmaceutical Inc (NASDAQ: BMRN). 
Additionally, during the first quarter of this year, John Chiplin and
Herm Rosenman, were appointed as independent board members. Dr.
Chiplin is currently CEO of Polynoma, Inc., and was founding CEO of
Arana Therapeutics prior to its acquisition by Cephalon for $329
million. In addition to serving on a number of public and private
boards, Mr. Rosenman was Senior Vice President and Chief Financial
Officer of Gen-Probe, Inc., until its acquisition by Hologic, Inc.,
in August 2012 for $3.7 billion. 
"We believe that having strengthened our intellectual property
portfolio, obtaining clinical data from 18 patients treated in our
CHF trial, and attaining FDA clearance to begin a CLI trial, has
increased our value to the investment community," said Dr. Lewis.
"The filing of the Form 10 represents the next step in our growth,
which will position us to attract institutional investment and Wall
Street support." 
The Company's Form 10 and accompanying exhibits filed with the
Securities and Exchange Commission can be found at: 
About Medistem, Inc. 
Medistem, Inc., is developing ERC-124, a universal stem cell product
derived from the endometrium. ERC-124 possesses specialized abilities
to stimulate new blood vessel formation and can differentiate into
lung, liver, heart, brain, bone, cartilage, fat and pancreatic
tissue. These unique properties have applications for treatment of
critical limb ischemia (CLI), congestive heart failure (CHF),
neurodegenerative diseases, liver failure, kidney failure, and
diabetes. ERC-124 has been cleared by the FDA to begin a CLI clinical
trial in the United States. In January 2012, the Company announced
the initiation of its RECOVER-ERC (Non-Revascularizable IschEmic
Cardiomyopathy treated with Retrograde COronary Sinus Venous DElivery
of Cell TheRapy) a double blind, placebo controlled, clinical trial.
This trial is being conducted at the Bakulev Scientific Center for
Cardiovascular Surgery, Moscow, Russia. The trial is a 60 patient
double blind placebo controlled study evaluating safety and efficacy
of ERC-124 in end stage CHF patients.  
Certain statements herein may be forward-looking and involve risks
and uncertainties. Such forward-looking statements involve
assumptions, known and unknown risks, uncertainties and other factors
which may cause the actual results, performance or achievements of
Medistem, Inc. These can be identified by the use of forward-looking
words, such as "believes", "expects", "may", "intends",
"anticipates", "plans", "estimates", or any other analogous or
similar expressions intended to identify forward-looking statements.
These forward-looking statements and estimates as to future
performance, estimates, and other statements contained herein
regarding matters that are not historical facts, are only predictions
and actual events or results may differ materially. We cannot assure
or guarantee that any future results described in this presentation
will be achieved, and actual results could differ materially as a
result of a variety of factors, including the risks associated with
the effect of changing economic conditions and other risk factors
detailed in the Company's Securities and Exchange Commission filings.
The Company undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise. 
John P. Salvador
Press spacebar to pause and continue. Press esc to stop.